Cancer treatment—androgen deprivation therapy purpose, code N

Exported from METEOR (AIHW's Metadata Online Registry)
© Australian Institute of Health and Welfare 2024
This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have

made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AlHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Cancer treatment—androgen deprivation therapy purpose, code N

Identifying and definitional attributes

Metadata item type: Data Element

Short name: Androgen deprivation therapy purpose

METEOR identifier: 505510

Registration status: Health!, Standard 14/05/2015

Definition: The purpose of <u>androgen deprivation therapy</u> (ADT) used in the treatment of

cancer, as represented by a code.

Context: Androgen deprivation therapy is used to treat people with prostate cancer.

Data Element Concept: Cancer treatment—androgen deprivation therapy purpose

Value Domain: Androgen deprivation therapy purpose code N

Value domain attributes

Representational attributes

Representation class: Code

Data type: Number

Format: N

Maximum character length: 1

ValueMeaningPermissible values:1Neo-adjuvant2Adjuvant3Salvage4PalliativeSupplementary values:8Unknown

Collection and usage attributes

Guide for use:

This code set outlines the purpose of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.

CODE 1 Neo-adjuvant

This code should be recorded when androgen deprivation therapy (ADT) is used prior to the main treatment.

CODE 2 Adjuvant

This code should be recorded when androgen deprivation therapy (ADT) is used after the main treatment.

CODE 3 Salvage

This code should be recorded when androgen deprivation therapy (ADT) is used after a recurrence of prostate cancer for a patient who has had a radical prostatectomy.

CODE 4 Palliative

This code should be recorded when androgen deprivation therapy (ADT) is used to manage and alleviate symptoms and control tumour growth in palliative patients.

CODE 9 Unknown

This code should be recorded when androgen deprivation therapy (ADT) has been used in the treatment of a patient but the purpose of the therapy is not ascertainable from the data source.

Source and reference attributes

Submitting organisation: Cancer Australia

Data element attributes

Collection and usage attributes

Guide for use: Record whether androgen deprivation therapy was used in the treatment of a

person with cancer. Where patients have recieved androgen deprivation therapy for

multiple purposes record this item multiple times.

Androgen hormones stimulate the growth of prostate cancer cells, and so the reduction of androgen hormones aims to reduce the spread of prostate cancer. This includes both chemical treatments, such as Luteinizing hormone-releasing

hormone agonists and antagonists, and surgical treatment, such as an

orchiectomy.

Collection methods: Collect from patient medical records.

Source and reference attributes

Submitting organisation: Cancer Australia

Relational attributes

Specifications:

Implementation in Data Set Prostate cancer (clinical) NBPDS Health!, Standard 14/05/2015

Conditional obligation:

Collect this item when Cancer treatment—androgen deprivation therapy, yes/no/not applicable code N equals yes.